Educational Wellness Information Only
This platform provides peer-reviewed research summaries and educational content about peptides for wellness and optimization purposes. Nothing on this site is intended as medical advice, diagnosis, or treatment. We do not claim any peptide can diagnose, treat, cure, or prevent any disease. Always consult a licensed healthcare provider before beginning any wellness protocol.
Statements on this site have not been evaluated by the FDA. Compounded preparations are subject to applicable state and federal regulations. Availability and eligibility vary.
Tesamorelin Peptide
GHRH analog FDA-approved for HIV-associated visceral fat.
What is Tesamorelin?
Tesamorelin is a growth hormone axis peptide studied for visceral adipose tissue reduction (approved) and cognitive function in older adults (research). Below is an educational overview of Tesamorelin peptide benefits, mechanism, common research protocols, dosage references, and known side effects.
Plain-Language Label Highlights
Brand names: Egrifta, Egrifta SV
Reducing excess belly fat in adults with HIV-related lipodystrophy.
A daily injection that tells your body to make more of its own growth hormone, which can shrink deep belly fat caused by HIV medications.
- •Joint pain
- •Redness or itching at injection site
- •Muscle pain
- •Swelling in arms/legs
- •Tingling
- •Higher blood sugar / new or worsening diabetes
- •Fluid retention
- •Possible growth of hidden tumors (use caution with cancer history)
- •You have active cancer
- •You have a pituitary tumor or recent pituitary surgery
- •You are pregnant
Educational summary of the FDA prescribing information. Not a substitute for the full label or medical advice. Always discuss with a licensed prescriber.
Tesamorelin Mechanism of Action
A stabilized analog of growth hormone-releasing hormone (GHRH) that stimulates pulsatile endogenous GH and IGF-1 release. FDA-approved (Egrifta) for the reduction of excess abdominal visceral fat in HIV-infected patients with lipodystrophy.
Tesamorelin Research Areas & Benefits
Tesamorelin Dosage & Common Research Protocols
2 mg subcutaneous daily in the approved HIV-lipodystrophy indication.
Protocols summarized for educational reference from published research. Not dosing guidance.
Tesamorelin Studies & Cited Research
Tesamorelin for HIV-associated lipodystrophy
Phase 3 trials showing significant visceral fat reduction.
Why we trust this source: Published in a peer-reviewed scientific journal with editorial and reviewer oversight.
Tesamorelin and NAFLD in HIV
Reduced hepatic fat fraction in HIV-infected adults with NAFLD.
Why we trust this source: Published in a peer-reviewed scientific journal with editorial and reviewer oversight.
Citations are linked to PubMed, Google Scholar, and Crossref searches so you can verify the source independently. All references are reviewed during our editorial passes (last reviewed June 1, 2026).
Tesamorelin Side Effects & Safety Considerations
- •FDA-approved only for HIV-associated lipodystrophy.
- •May affect glucose tolerance; monitor in at-risk patients.
- •Requires physician oversight.
Common questions about Tesamorelin
More Performance peptides · See all 14
Educational Information Only — Not Medical Advice
All content on this page is for educational and informational purposes only. It is not medical advice, diagnosis, or treatment. We make no claims that any peptide can diagnose, treat, cure, or prevent any disease. Peptides discussed are not FDA-approved for the indications listed unless explicitly stated otherwise.
Always consult a licensed healthcare provider before beginning any wellness protocol. Statements have not been evaluated by the FDA. Compounded preparations are subject to applicable state and federal regulations. Availability, eligibility, and pricing may vary.
Ask the Library
Ask anything about peptides — answers come from our curated reference library with citations.